Atossa Reports Full I-SPY 2 Study Results on Low-Dose (Z)-Endoxifen
Details : (Z)-endoxifen is a highly potent Selective Estrogen Receptor Modulator (SERM) with demonstrated ability to inhibit—and potentially degrade—estrogen receptors.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2025
Lead Product(s) : Endoxifen
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Endoxifen
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 23, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2022
Lead Product(s) : Endoxifen
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : Endoxifen
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients
Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Endoxifen
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Karolinska Institutet
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : Endoxifen
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Karolinska Institutet
Deal Size : Inapplicable
Deal Type : Inapplicable